Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences has reported Total Non-Current Liabilities for 17 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 27.57% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 27.57% YoY), and the FY2025 full-year result was $1.2 billion, up 20.35% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $1.2 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.2 billion in Q1 2026, with the low at $554.3 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $834.1 million across 5 years, with a median of $777.5 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities retreated 14.49% — and 2025, when it soared 56.57%.
• Neurocrine Biosciences' Total Non-Current Liabilities stood at $631.2 million in 2022, then surged by 44.66% to $913.1 million in 2023, then climbed by 5.44% to $962.8 million in 2024, then advanced by 20.35% to $1.2 billion in 2025, then rose by 6.84% to $1.2 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.